诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NVO 诺和诺德

交易中 02-25 15:54:28 EST

38.12

-0.47

-1.23%

最高38.24	最低37.65	成交量5,110万
今开37.70	昨收38.59	日振幅1.53%
总市值1,692亿	流通市值1,215亿	总股本44.39亿
成交额19.40亿	换手率1.60%	流通股本31.88亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NVO","market":"US","secType":"STK","nameCN":"诺和诺德","latestPrice":38.115,"timestamp":1772052868212,"preClose":38.59,"halted":0,"volume":51096511,"delay":0,"changeRate":-0.0123088883130345,"floatShares":3187922885,"shares":4439052849,"eps":3.620568,"marketStatus":"交易中","change":-0.475,"latestTime":"02-25 15:54:28 EST","open":37.7,"high":38.24,"low":37.65,"amount":1939714356.060047,"amplitude":0.015289,"askPrice":38.12,"askSize":1474,"bidPrice":38.11,"bidSize":2312,"shortable":3,"etf":0,"ttmEps":3.620568,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1772053200000},"marketStatusCode":2,"adr":1,"adrRate":1,"listingDate":363499200000,"exchange":"NYSE","adjPreClose":38.59,"dividendRate":0.045177,"preHourTrading":{"tag":"盘前","latestPrice":37.7,"preClose":38.59,"latestTime":"09:29 EST","volume":2266894,"amount":85797800.81844999,"timestamp":1772029799999,"change":-0.89,"changeRate":-0.023063,"amplitude":0.014252},"postHourTrading":{"tag":"盘后","latestPrice":38.8,"preClose":38.59,"latestTime":"19:59 EST","volume":319715,"amount":12352462.682,"timestamp":1771981194250,"change":0.21,"changeRate":0.005442,"amplitude":0.006478},"volumeRatio":1.483375,"optionData":{"bulkOrders":[{"symbol":"NVO","call":false,"expireDate":1789704000000,"strike":"30.0","timestamp":1772032795543,"price":2.05,"volume":2800,"amount":574000,"type":"+"},{"symbol":"NVO","call":false,"expireDate":1789704000000,"strike":"35.0","timestamp":1772051098854,"price":3.92,"volume":2000,"amount":784000,"type":"-"}]},"impliedVol":0.5093,"impliedVolPercentile":0.502},"requestUrl":"/m/hq/s/NVO/wiki","defaultTab":"wiki","newsList":[{"id":"1105563536","title":"这四张图表展示了诺和诺德当前的困境规模","url":"https://stock-news.laohu8.com/highlight/detail?id=1105563536","media":"老虎资讯综合","labels":["corporation","movement"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105563536?lang=zh_cn&edition=full","pubTime":"2026-02-25 23:29","pubTimestamp":1772033344,"startTime":"0","endTime":"0","summary":"诺和诺德是首家研制出用于减肥的GLP-1药物的公司，并一度成为欧洲市值最高的企业。尽管率先推出了用于减肥的GLP-1药物，但诺和诺德的市场份额已被侵蚀。诺和诺德对其面临的挑战，尤其是定价方面的挑战，有着清醒的认识。以下图表展示了诺和诺德所面临挑战的规模。诺和诺德通常被视为一家专注于糖尿病和肥胖症领域的纯业务公司。诺和诺德表示对该药物持乐观态度，并将通过进一步试验来评估其全部减肥潜力。","market":"us","thumbnail":"https://community-static.tradeup.com/news/1d88a89585f427c3418708220ab3f4d6","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/1d88a89585f427c3418708220ab3f4d6"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"这四张图表展示了诺和诺德当前的困境规模","news_tag":"corporation,movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO"],"gpt_icon":1},{"id":"2614295080","title":"诺和诺德(NVO.US)斥资最高21亿美元携手Vivtex，加码下一代口服减肥药","url":"https://stock-news.laohu8.com/highlight/detail?id=2614295080","media":"智通财经","labels":["corporation"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614295080?lang=zh_cn&edition=full","pubTime":"2026-02-25 21:42","pubTimestamp":1772026931,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，丹麦制药商诺和诺德周三表示，已与总部位于美国的Vivtex公司达成一项价值高达21亿美元的合作协议，共同开发用于治疗肥胖症和糖尿病的下一代口服药物。据了解，此次合作的核心价值在于Vivtex所拥有的颠覆性口服给药研发平台。两家公司表示，Vivtex的平台利用肠道筛选检测、递送技术及人工智能工具，助力生物药物实现片剂化给药。诺和诺德目前提供用于治疗肥胖症和2型糖尿病的GLP-1药物，包括Wegovy、Ozempic及口服糖尿病药物Rybelsus。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1407309.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"诺和诺德(NVO.US)斥资最高21亿美元携手Vivtex，加码下一代口服减肥药","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4532","LU0154236417.USD","NVO","NVOH","LU1093756325.SGD","IE00BKVL7J92.USD","LU1093756168.USD","NVOX","IE00BZ1G4Q59.USD","BK4599","BK4588","BK4585","BK4007"],"gpt_icon":1},{"id":"2614820570","title":"诺和诺德宣布与生物制药公司Vivtex达成合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2614820570","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614820570?lang=zh_cn&edition=full","pubTime":"2026-02-25 21:06","pubTimestamp":1772024794,"startTime":"0","endTime":"0","summary":null,"market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4532","BK4588","LU1093756168.USD","NVO","IE00BZ1G4Q59.USD","LU0154236417.USD","BK4585","LU1093756325.SGD","IE00BKVL7J92.USD","NVOH","BK4007","BK4599","NVOX"],"gpt_icon":0},{"id":"2614208997","title":"诺和诺德惊心24小时：减肥药的下一个主战场在哪？","url":"https://stock-news.laohu8.com/highlight/detail?id=2614208997","media":"药创新","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614208997?lang=zh_cn&edition=full","pubTime":"2026-02-25 18:50","pubTimestamp":1772016613,"startTime":"0","endTime":"0","summary":"然而剧情在24小时内急转直上：诺和诺德携手联邦制药宣布，三受体激动剂UBT251在中国的II期减重试验大获成功。24周治疗后，受试者平均减重19.7%，相当于甩掉了17.5公斤的负担，而安慰剂组仅减轻2%。在最高剂量12mg组，retatrutide在68周时实现平均28.7%的体重下降，显著高于安慰剂组的2.1%；9mg组的减重幅度为26.4%。TRIUMPH-4的另一个特点在于其并未将减重作为唯一关注点。总体停药率在高剂量组中最高达到18.2%，其中一部分与不良反应相关，且停药率与基线BMI相关。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602251955319541f51c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602251955319541f51c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4532","IE00BKVL7J92.USD","BK4585","LU0154236417.USD","NVO","NVOX","LU1093756325.SGD","IE00BZ1G4Q59.USD","BK4599","LU1093756168.USD","NVOH","BK4588","BK4007"],"gpt_icon":1},{"id":"2614554709","title":"【市场】17个国谈药拟进院，独家品种霸屏","url":"https://stock-news.laohu8.com/highlight/detail?id=2614554709","media":"米内网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614554709?lang=zh_cn&edition=full","pubTime":"2026-02-25 16:07","pubTimestamp":1772006826,"startTime":"0","endTime":"0","summary":"精彩内容近日，成都市第六人民医院发布招标公示，将组织拟引入药品生产企业遴选工作。17个新药在列，均为国谈药，涵盖化学药及生物药，既有环泊酚注射液等超10亿大品种，亦有芦比前列酮软胶囊、替戈拉生片等2025年前三季度销售额增速达三位数的高增长品种。17个新药均为国谈药，目前均已纳入国家医保乙类目录，主要集中在消化系统及代谢、神经系统、心脑血管系统等治疗领域，可见以慢病药、常见病药为主。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602251615059541ed56&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602251615059541ed56&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1093756168.USD","002653","IE00BZ1G4Q59.USD","600276","NVOX","NVS","BK4007","002793","BK4532","01276","NVOH","LU0154236417.USD","BK4585","NVO","LU1093756325.SGD","IE00BKVL7J92.USD","BK4599","BK4588"],"gpt_icon":1},{"id":"2614778191","title":"Tides 速递 | 24周减重19.7%！联邦制药 × 诺和诺德GLP-1/GIP/GCG 三靶点激动剂减重II期研究成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2614778191","media":"多肽圈","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614778191?lang=zh_cn&edition=full","pubTime":"2026-02-25 09:26","pubTimestamp":1771982766,"startTime":"0","endTime":"0","summary":"｜中肽生化内容团队编辑2026年2月24日，联邦制药国际控股有限公司与Novo Nordisk A/S联合发布GLP-1/GIP/GCG三靶点受体激动剂UBT251中国II期临床研究的主要结果。诺和诺德还计划于2026年下半年启动一项针对2型糖尿病患者的UBT251的II期临床研究。基于该研究结果，联邦制药计划启动一项针对中国超重或肥胖患者的III期临床研究。2025年3月，联邦生物与诺和诺德就UBT251达成独家许可协议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022509412297a6ea55&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022509412297a6ea55&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVO","BK1191","03933"],"gpt_icon":1},{"id":"2614272820","title":"诺和诺德宣布拟进行私募配售","url":"https://stock-news.laohu8.com/highlight/detail?id=2614272820","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614272820?lang=zh_cn&edition=full","pubTime":"2026-02-25 04:57","pubTimestamp":1771966624,"startTime":"0","endTime":"0","summary":"诺和诺德宣布拟进行私募配售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225050815a71b1c34&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225050815a71b1c34&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4588","BK4007","NVOX","BK4599","LU0154236417.USD","NVO","IE00BZ1G4Q59.USD","LU1093756168.USD","IE00BKVL7J92.USD","NVOH","LU1093756325.SGD","BK4532"],"gpt_icon":0},{"id":"1154190688","title":"诺和诺德拟将Ozempic、Wegovy美国定价最高下调50% 礼来股价应声下跌1.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=1154190688","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154190688?lang=zh_cn&edition=full","pubTime":"2026-02-24 22:37","pubTimestamp":1771943830,"startTime":"0","endTime":"0","summary":"据消息称，丹麦制药巨头诺和诺德计划将其明星产品Ozempic与Wegovy在美国市场的标价最高下调50%，这一举措立即在资本市场引发连锁反应。其主要竞争对手礼来的股价应声下挫1.2%，显示出市场对潜在价格战可能挤压行业利润的担忧。\n此次价格调整若属实，将显著提升诺和诺德旗下两款热门GLP-1药物在美国市场的可及性与竞争力。分析人士指出，降价策略可能旨在进一步扩大市场份额，并对礼来同类产品Mounjaro和Zepbound构成直接压力。投资者正密切关注事态发展，评估此举对全球减肥药及糖尿病治疗领域竞争格局的深远影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b9030c47a641b4d32c695499220ff2c5","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0943347566.SGD","LU1548497426.USD","LU2237443465.HKD","BK4007","IE0001KFT4U8.USD","LU0106261372.USD","LU2237443622.USD","LU2462157665.USD","IE00BJLML261.HKD","LU1267930730.SGD","IE00B1BXHZ80.USD","LU2237443978.SGD","LU0385154629.USD","IE0004445239.USD","LU0109391861.USD","LU0889565916.HKD","LU0320765992.SGD","IE00B4R5TH58.HKD","LU0882574139.USD","LU1804176565.USD","LU1093756168.USD","LU2265009873.SGD","LU2361044865.SGD","LU0058720904.USD","LU2089284900.SGD","LU2552382215.SGD","LU1720051017.SGD","SGXZ51526630.SGD","LU0353189763.USD","LU0323591593.USD","ELIS","SG9999013999.USD","LU2106854487.HKD","SG9999001176.SGD","LU2213496289.HKD","SGXZ31699556.SGD","LU1868837300.USD","LU2324357040.USD","LU2089984988.USD","LU0466842654.USD","IE00B7KXQ091.USD","LU2552382058.USD","LU2271345857.HKD","LU1868837136.USD","LU0882574055.USD","LU0964807845.USD","LU0353189680.USD","LU2237443549.SGD","SG9999018857.SGD","LU1061106388.HKD","LU2750360997.AUD","LU1366192091.USD","LU1623119135.USD","LU2237443382.USD","LU2417539215.USD","GB00BDT5M118.USD","LU0096364046.USD","LU1868836914.USD","SG9999001176.USD","SG9999014914.USD","LU0198837287.USD","LU2491050154.USD","LU2023250504.SGD","LU0006306889.USD","LU0266013472.USD","LU2357305700.SGD","IE00BJJMRY28.SGD","LU2237438978.USD","LU1917777945.USD","LU1280957306.USD","LU0786609619.USD","SG9999015952.SGD","LU1629891620.HKD","LU0708995401.HKD","IE00B4JS1V06.HKD","IE00B775H168.HKD","SG9999014880.SGD","LU2168564149.EUR","SGXZ99366536.SGD","IE0005OL40V9.USD","LU0122379950.USD","LU0689472784.USD","LU2756315318.SGD","LU0203201768.USD","LU1069344957.HKD","LU2468319806.SGD","LU1093756325.SGD","BK4534","SGXZ57979304.SGD","NVO","IE00B2B36J28.USD","LU0234572021.USD","LU0823434583.USD","LU2111349929.HKD","IE00BN29S564.USD","SG9999017495.SGD","LU1551013425.SGD","LU0061475181.USD","LU2746668461.USD","LU2756315664.SGD","LU1868836591.USD","LU2211815571.USD","LU0683600562.USD","LU2361044949.HKD","LU2471134879.HKD","LU1712237335.SGD","LU2023251221.USD","LU0823416689.USD","LU2896262040.SGD","IE0004445015.USD","LU2087625088.SGD","LU2168564222.USD","LU0456855351.SGD","LU2471134952.CNY","LU0354030511.USD","LU2168564495.EUR","BK4533","LU0210536198.USD","LU0114720955.EUR","LU2746668974.SGD","IE00BFSS8Q28.SGD","LU0158827781.USD","LU1988902786.USD","LU2750360641.GBP","LU0471298694.HKD","BK4588","BK4516","SG9999015945.SGD","LU2108987350.USD","LU1232071149.USD","SGXZ81514606.USD","LU1983299246.USD","LU2168564065.EUR","LU0820561909.HKD","BK4581","IE00BJJMRX11.SGD","LU0097036916.USD","LU0225283273.USD","LU0238689110.USD","LU2361045086.USD","LU2168563687.JPY","IE00BJT1NW94.SGD","IE00B1XK9C88.USD","IE00BFTCPJ56.SGD","LU0256863811.USD","LU1291159041.SGD","LU0471298777.SGD","LU2491050071.SGD","LU1551013342.USD","BK4599","IE0009355771.USD","IE0002141913.USD","LLII","LU1814569148.SGD","BK4585","LU0316494557.USD","SG9999015986.USD","LU1720051108.HKD","IE00BFSS7M15.SGD","LU0787776722.HKD","LU0820561818.USD","LU0820562030.AUD","SG9999015978.USD","ELIL","LU2028103732.USD","LLY","LU2360106947.USD","SG9999014906.USD","LU2023250330.USD","LU2237443895.HKD","LU2491049909.HKD","IE00BKDWB100.SGD","LLYX","LU2089283258.USD","LU0203202063.USD","LU0289739699.SGD","LU0672654240.SGD","LU2264538146.SGD","LU1057294990.SGD","LU2456880835.USD","LU2063271972.USD","IE00BJJMRZ35.SGD","LU2112291526.USD","LU0640476718.USD","LU1064131342.USD","LU2461242641.AUD","LU1035775433.USD","LU0094547139.USD","IE00BK4W5L77.USD","LU0079474960.USD","LU0109394709.USD","LU1127390331.HKD","LU2471134523.USD","LU0256863902.USD","LU1023059063.AUD","SG9999014898.SGD","LU1145028129.USD","LU2236285917.USD","LU0354030438.USD","LLYZ","LU1868836757.USD","LU1989771016.USD","LU0417517546.SGD","SG9999018865.SGD","IE00BWXC8680.SGD","LU1974910355.USD","LU2471134796.USD","IE00BK4W5M84.HKD","LU0158827948.USD","LU1323610961.USD","LU2552382132.HKD","LU2602419157.SGD","IE00BKPKM429.USD","LU0320765059.SGD","LU0432979614.USD","LU0823434740.USD"],"gpt_icon":0},{"id":"2613748506","title":"诺和诺德盘中异动 早盘股价大跌2.86%报38.50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2613748506","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613748506?lang=zh_cn&edition=full","pubTime":"2026-02-24 22:32","pubTimestamp":1771943563,"startTime":"0","endTime":"0","summary":"北京时间2026年02月24日22时32分，诺和诺德股票出现异动，股价快速下挫2.86%。截至发稿，该股报38.50美元/股，成交量737.429万股，换手率0.17%，振幅0.71%。诺和诺德股票所在的制药行业中，整体跌幅为0.30%。诺和诺德公司简介：诺和诺德在全球品牌糖尿病治疗市场中占据大约三分之一的份额，是世界上领先的糖尿病护理产品供应商。诺和诺德还拥有一个生物制药部门，专注于治疗血友病和其他疾病的蛋白质疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224223243a71a5305&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224223243a71a5305&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ1G4Q59.USD","LU1093756325.SGD","BK4588","NVOX","NVOH","BK4532","IE00BKVL7J92.USD","LU0154236417.USD","BK4599","NVO","BK4007","LU1093756168.USD","BK4585"],"gpt_icon":1},{"id":"2613712854","title":"价格战打响！诺和诺德(NVO.US)明年起在美大幅下调减肥药标价 狙击礼来(LLY.US)夺回市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2613712854","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613712854?lang=zh_cn&edition=full","pubTime":"2026-02-24 21:31","pubTimestamp":1771939893,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺和诺德计划于明年大幅下调旗下两款重磅药物Wegovy和Ozempic的美国官方定价，以在肥胖症治疗市场争夺更大份额。此次降价针对的是批发采购成本，这一公开标价并不反映美国市场复杂的返利体系。目前，诺和诺德正在价格方面多措并举，以提升在肥胖症领域的竞争力。新价格将于明年1月1日生效。Millar表示，公司需要现在宣布降价，以便让付款方有时间应对明年的变化。Millar强调，两次降价相互独立，并无关联。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406860.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BK4W5L77.USD","BK4533","LU2491050071.SGD","LU0210536198.USD","LU2168563687.JPY","ELIL","LU2023250504.SGD","LU2471134952.CNY","LLYZ","LU2089284900.SGD","LU2271345857.HKD","LU2552382058.USD","LU0058720904.USD","LU0114720955.EUR","IE0009355771.USD","IE0004445239.USD","LU1023059063.AUD","LU0820562030.AUD","NVOX","LU2168564222.USD","LU2456880835.USD","LU0417517546.SGD","LU1551013342.USD","LU1983299246.USD","LU0238689110.USD","BK4007","LU0289739699.SGD","LU1061106388.HKD","NVO","ELIS","NVOH","LLY","IE00BJJMRZ35.SGD","LU0432979614.USD","LU1917777945.USD","BK4599","LU0106261372.USD","LU2237443549.SGD","LLII","LU2168564149.EUR","LU0203202063.USD","LU1720051108.HKD","LU2602419157.SGD","LU0320765992.SGD","LU1145028129.USD","LU2756315318.SGD","IE00BK4W5M84.HKD","LLYX","SG9999013999.USD","LU2168564065.EUR"],"gpt_icon":1},{"id":"2613171180","title":"礼来盘前下跌 诺和诺德将下调Ozempic和Wegovy在美国的价格","url":"https://stock-news.laohu8.com/highlight/detail?id=2613171180","media":"环球市场播报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613171180?lang=zh_cn&edition=full","pubTime":"2026-02-24 20:53","pubTimestamp":1771937580,"startTime":"0","endTime":"0","summary":"礼来股价在盘前交易中一度迅速下跌4.1%，此前据《华尔街曰报》报道，竞争对手诺和诺德计划将Ozempic和Wegovy在美国市场的定价下调至多50%。\n　　《华尔街曰报》报道，上述糖尿病及减肥治疗药物自2027年1月1日起，每月定价均将调整为675美元\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：郭明煜","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b9030c47a641b4d32c695499220ff2c5","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-02-24/doc-inhnxnuf1949059.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4007","LU0234572021.USD","LU1069344957.HKD","IE00BK4W5M84.HKD","LU0432979614.USD","LU2063271972.USD","LU0096364046.USD","LU1983299246.USD","LU2028103732.USD","IE00BKDWB100.SGD","LU0158827948.USD","LU1868837300.USD","LU1868836757.USD","LU0266013472.USD","LU0203202063.USD","LU1548497426.USD","IE0001KFT4U8.USD","IE00BKPKM429.USD","LU0316494557.USD","LU1023059063.AUD","LU1093756168.USD","LU0114720955.EUR","LU0823434583.USD","LU2087625088.SGD","LU2896262040.SGD","LU1712237335.SGD","SGXZ99366536.SGD","IE00BJJMRX11.SGD","LU0256863811.USD","IE00BFSS8Q28.SGD","LU0320765059.SGD","LU2756315664.SGD","LU2236285917.USD","LU2552382215.SGD","LU1267930730.SGD","LU2089283258.USD","LU2089984988.USD","SG9999015945.SGD","LU2360106947.USD","BK4585","LU1291159041.SGD","SG9999014914.USD","LU0106261372.USD","LU2023251221.USD","SGXZ31699556.SGD","LU0154236417.USD","IE00B4R5TH58.HKD","LU0323591593.USD","LU0708995401.HKD","LU0943347566.SGD","LU1720051108.HKD","LU2108987350.USD","LU2491049909.HKD","BK4534","LU2361044865.SGD","LU0683600562.USD","LU1804176565.USD","LU2361044949.HKD","LU0882574139.USD","SG9999015952.SGD","IE0002141913.USD","LU2168563687.JPY","SG9999014880.SGD","IE00B775H168.HKD","BK4533","IE0004445015.USD","LU1093756325.SGD","LU0320765992.SGD","SG9999014906.USD","LU2168564495.EUR","LU1280957306.USD","LU2271345857.HKD","LU2237443978.SGD","LU0353189763.USD","LU1623119135.USD","LU2168564149.EUR","IE00BWXC8680.SGD","LU0820561818.USD","LU2456880835.USD","LU2361045086.USD","LU1917777945.USD","LU2237443895.HKD","LU2471134796.USD","GB00BDT5M118.USD","LU2112291526.USD","IE00BZ1G4Q59.USD","LU2750360997.AUD","LU1989771016.USD","LU2168564065.EUR","LU1868836914.USD","IE00B1BXHZ80.USD","LU0061475181.USD","LU1057294990.SGD","SGXZ57979304.SGD","LU0198837287.USD","LU1323610961.USD","SG9999015986.USD","LU1035775433.USD","LU2746668974.SGD","BK4532","LU2750360641.GBP","IE00BK4W5L77.USD","IE00BJLML261.HKD","LU2417539215.USD","LU2491050071.SGD","SG9999001176.SGD","LU1366192091.USD","BK4599","LU0203201768.USD","LU1127390331.HKD","IE0009355771.USD","LU0006306889.USD","IE00BJJMRZ35.SGD","BK4581","LU1868837136.USD","IE0004445239.USD","LU2237443465.HKD","SG9999017495.SGD","LU2471134879.HKD","LU0094547139.USD","LU0353189680.USD","IE0005OL40V9.USD","LU0109394709.USD","LU0787776722.HKD","LU0820562030.AUD","LU0097036916.USD","IE00BJT1NW94.SGD","LU2237443382.USD","SG9999018857.SGD","LU2168564222.USD","LU0417517546.SGD","LU0122379950.USD","LU2213496289.HKD","IE00BN29S564.USD","LU0882574055.USD","LU2023250330.USD","LU0354030511.USD","LU2237443549.SGD","LU2471134523.USD","SG9999015978.USD","LU0225283273.USD","LU1551013425.SGD","LU1720051017.SGD","LU2468319806.SGD","SG9999013999.USD","IE00B7KXQ091.USD","LU0640476718.USD","LU2462157665.USD","LU0786609619.USD","LU1814569148.SGD","NVOX","LU0158827781.USD","LU2461242641.AUD","LLYX","SG9999001176.USD","LU2552382058.USD","LU0689472784.USD","LU0456855351.SGD","IE00BKVL7J92.USD","LU1974910355.USD","LU2746668461.USD","BK4516","LU1232071149.USD","LU1629891620.HKD","LU0471298777.SGD","LU2237443622.USD","LU0289739699.SGD","IE00B2B36J28.USD","SGXZ81514606.USD","LU0823434740.USD","LU0889565916.HKD","LU0672654240.SGD","LU2357305700.SGD","BK4588","ELIS","IE00B1XK9C88.USD","LLYZ","LU0820561909.HKD","LU0238689110.USD","LU2756315318.SGD","NVOH","LU0210536198.USD","IE00BFTCPJ56.SGD","LU2089284900.SGD","LU2471134952.CNY","LU0385154629.USD","LU0964807845.USD","LU0471298694.HKD","LU0823416689.USD","LLY","LU2552382132.HKD","LU0256863902.USD","ELIL","LU2023250504.SGD","LU0058720904.USD","LU0079474960.USD","LU1868836591.USD","IE00B4JS1V06.HKD","LU2602419157.SGD","LU2265009873.SGD","LU2491050154.USD","SG9999014898.SGD","LU1145028129.USD","LU2111349929.HKD","SGXZ51526630.SGD","IE00BFSS7M15.SGD","LU0354030438.USD","LU2211815571.USD","LU2324357040.USD","LU1988902786.USD","LU2237438978.USD","NVO","LU1061106388.HKD","LU2264538146.SGD","LU0466842654.USD","IE00BJJMRY28.SGD","LLII","LU2106854487.HKD","SG9999018865.SGD","LU0109391861.USD","LU1064131342.USD","LU1551013342.USD"],"gpt_icon":0},{"id":"2613711325","title":"诺和诺德美股盘前下跌3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613711325","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613711325?lang=zh_cn&edition=full","pubTime":"2026-02-24 20:43","pubTimestamp":1771936992,"startTime":"0","endTime":"0","summary":"每经AI快讯，2月24日，诺和诺德美股盘前下跌3%，公司将司美格鲁肽（Wegovy）在美售价下调50%，至每月675美元。每日经济新闻","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224204542a4c31745&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"b9030c47a641b4d32c695499220ff2c5","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224204542a4c31745&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4581","IE00BKVL7J92.USD","BK4007","BK4588","BK4599","TWM","RWM","BK4534","BK4585","UWM","NVOH","LU1093756168.USD","IE00BZ1G4Q59.USD","NVO","MNQmain","TNA","IWO","NVOX","LU0154236417.USD","SRTY","BK4535","BK4550","IWN","TZA","BK4532","LU1093756325.SGD"],"gpt_icon":0},{"id":"1108091979","title":"诺和诺德计划在美大幅下调减肥药标价，狙击礼来，夺回市场","url":"https://stock-news.laohu8.com/highlight/detail?id=1108091979","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108091979?lang=zh_cn&edition=full","pubTime":"2026-02-24 20:42","pubTimestamp":1771936928,"startTime":"0","endTime":"0","summary":"带来更好的获取途径和更高的可负担性。","market":"us","thumbnail":"https://static.tigerbbs.com/a7bd67b6d6b09271dab6332df6a9ee65","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/a7bd67b6d6b09271dab6332df6a9ee65"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b9030c47a641b4d32c695499220ff2c5","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO","LLY"],"gpt_icon":0},{"id":"2613584719","title":"诺和诺德将司美格鲁肽(Wegovy®)在美售价下调50%，至每月675美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2613584719","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613584719?lang=zh_cn&edition=full","pubTime":"2026-02-24 20:35","pubTimestamp":1771936542,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b9030c47a641b4d32c695499220ff2c5","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0154236417.USD","IE00BZ1G4Q59.USD","BK4007","IE00BKVL7J92.USD","BK4585","LU1093756325.SGD","BK4588","LU1093756168.USD","BK4599","NVOX","NVO","NVOH","BK4532"],"gpt_icon":0},{"id":"2613271339","title":"诺和诺德和联邦生物科技的新减肥药帮助患者减轻体重","url":"https://stock-news.laohu8.com/highlight/detail?id=2613271339","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613271339?lang=zh_cn&edition=full","pubTime":"2026-02-24 19:35","pubTimestamp":1771932900,"startTime":"0","endTime":"0","summary":"诺和诺德和联邦生物科技表示，二者联合开发的一款实验性肥胖症药物在中国的一项中期临床试验中帮助患者减轻了体重。　　诺和诺德和联邦生物科技的母公司联邦制药国际控股周二表示，在这项中国研究中，名为UBT251的药物在给药24周后，使患者平均体重减轻了最高19.7%。　　两家公司正根据去年3月签署的一项价值最高20亿美元的协议共同开发该药物，这是诺和诺德为补充其药物新产品永续规划而达成的数项交易之一。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f1cb9c263e4906c971f3030dfa725fa8","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-02-24/doc-inhnxnuh8710404.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0154236417.USD","IE00BZ1G4Q59.USD","01084","BK4007","BK4599","IE00BKVL7J92.USD","LU1093756325.SGD","BK4588","LU1093756168.USD","BK4585","NVOX","NVO","NVOH","BK4532"],"gpt_icon":1},{"id":"1187469747","title":"诺和诺德：三重激动剂UBT251在中国2期临床试验中，24周后平均体重降幅达19.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1187469747","media":"老虎资讯综合","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187469747?lang=zh_cn&edition=full","pubTime":"2026-02-24 16:48","pubTimestamp":1771922896,"startTime":"0","endTime":"0","summary":"今日，联邦制药国际控股有限公司与诺和诺德公司共同宣布了UBT251在中国进行的2期临床试验的顶线结果。试验数据显示，受试者基线平均体重为92.2公斤，治疗24周后，UBT251组观察到的平均体重降幅最高达19.7%，而安慰剂组则为2.0%。诺和诺德还预计将在2026年下半年启动针对2型糖尿病患者的UBT251 2期临床试验。患者被随机分配至每周接受一次皮下注射的UBT251 2毫克、4毫克、6毫克剂量组或安慰剂组，持续治疗24周。股价诺和诺德夜盘跌逾3%。","market":"us","thumbnail":"https://community-static.tradeup.com/news/fce1b54db0e994f757f74841ca4f70ea","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/fce1b54db0e994f757f74841ca4f70ea"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f37ea4482eb71651542a4cd5fb933659","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO"],"gpt_icon":1},{"id":"2613431767","title":"德银：将诺和诺德目标价下调至275丹麦克朗","url":"https://stock-news.laohu8.com/highlight/detail?id=2613431767","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613431767?lang=zh_cn&edition=full","pubTime":"2026-02-24 15:16","pubTimestamp":1771917363,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b9030c47a641b4d32c695499220ff2c5","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4532","BK4585","NVOX","IE00BZ1G4Q59.USD","NVOH","BK4588","NVO","LU1093756325.SGD","IE00BKVL7J92.USD","BK4599","BK4007","LU0154236417.USD","LU1093756168.USD"],"gpt_icon":0},{"id":"2613007764","title":"花旗：将诺和诺德目标价调至309丹麦克朗","url":"https://stock-news.laohu8.com/highlight/detail?id=2613007764","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613007764?lang=zh_cn&edition=full","pubTime":"2026-02-24 14:30","pubTimestamp":1771914618,"startTime":"0","endTime":"0","summary":"格隆汇2月24日丨花旗集团将诺和诺德目标价从340丹麦克朗下调至309丹麦克朗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224143338a4c1bd7b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":"03706a15d81bef9309ea01b6be64fbe0","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224143338a4c1bd7b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1244550577.SGD","LU2462157665.USD","LU0154236417.USD","LU1093756168.USD","LU1244550494.USD","IE00BSNM7G36.USD","BK4559","LU0052756011.USD","LU0648001328.SGD","NVO","NVOH","LU1506573853.SGD","LU2125154935.USD","NVOX","LU0320765646.SGD","IE00BZ1G4Q59.USD","LU0072461881.USD","LU0106831901.USD","BK4534","BK4532","LU0310800965.SGD","LU2125154778.USD","LU2236285917.USD","LU2417539215.USD","LU0130102774.USD","LU0130517989.USD","LU1668664300.SGD","BK4599","LU0162691827.USD","LU2456880835.USD","BK4207","LU0170899867.USD","LU1201861249.SGD","LU0098860793.USD","IE00BKVL7J92.USD","LU1162221912.USD","BK4007","LU0314106906.USD","LU1267930227.SGD","BK4588","BK4504","LU2360032135.SGD","LU0128525689.USD","LU0980610538.SGD","LU1791807156.HKD","LU1244550221.USD","LU1093756325.SGD","BK4566","BK4585","LU0477156953.USD","LU1366192091.USD"],"gpt_icon":0},{"id":"2613769464","title":"暴跌超16%！诺和诺德股价跌回“司美格鲁肽前时代”","url":"https://stock-news.laohu8.com/highlight/detail?id=2613769464","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613769464?lang=zh_cn&edition=full","pubTime":"2026-02-24 13:03","pubTimestamp":1771909380,"startTime":"0","endTime":"0","summary":"2026年对于诺和诺德而言是关键之年。该公司的司美格鲁肽市场份额正面临以礼来为首的多家竞争对手的挤压。在中国市场，司美格鲁肽的核心分子专利也将面临到期。　　诺和诺德当天股价收盘暴跌超过16%，不仅创下2021年6月以来新低，也抹去了上一代减重药司美格鲁肽上市以来的所有涨幅。届时该药物与已经获批的诺和诺德口服司美格鲁肽减重药的竞争将进一步加剧。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-02-24/doc-inhnwvwu3187198.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"b9030c47a641b4d32c695499220ff2c5","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-02-24/doc-inhnwvwu3187198.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4599","NVOH","BK4585","BK4007","BK4532","IE00BZ1G4Q59.USD","LU1093756325.SGD","NVOX","IE00BKVL7J92.USD","NVO","BK4588","LU0154236417.USD","LU1093756168.USD"],"gpt_icon":1},{"id":"2613535766","title":"小摩下调诺和诺德欧股评级至“中性”","url":"https://stock-news.laohu8.com/highlight/detail?id=2613535766","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613535766?lang=zh_cn&edition=full","pubTime":"2026-02-24 12:35","pubTimestamp":1771907740,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0154236417.USD","IE00BZ1G4Q59.USD","BK4007","IE00BKVL7J92.USD","BK4585","LU1093756325.SGD","BK4588","LU1093756168.USD","BK4599","NVOX","NVO","NVOH","BK4532"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.novonordisk.com","stockEarnings":[{"period":"1week","weight":-0.2184},{"period":"1month","weight":-0.3802},{"period":"3month","weight":-0.2078},{"period":"6month","weight":-0.3122},{"period":"1year","weight":-0.574},{"period":"ytd","weight":-0.2415}],"compareEarnings":[{"period":"1week","weight":0.0066},{"period":"1month","weight":-0.0027},{"period":"3month","weight":0.0113},{"period":"6month","weight":0.0592},{"period":"1year","weight":0.1509},{"period":"ytd","weight":0.008}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Novo Nordisk A/S成立于1989年，由两家丹麦公司Nordisk Gentofte A/S和Novo Industri A/S合并而成。该公司是一家全球性的医疗保健公司，也是肥胖和糖尿病护理、制造和营销包括GLP-1受体激动剂和现代胰岛素在内的医药产品的世界领先企业。总部位于丹麦，业务遍及约80个国家，产品销往约170个国家。","yearOnYearQuotes":[{"month":1,"riseRate":0.533333,"avgChangeRate":0.120105},{"month":2,"riseRate":0.6,"avgChangeRate":0.019646},{"month":3,"riseRate":0.454545,"avgChangeRate":0.006986},{"month":4,"riseRate":0.613636,"avgChangeRate":0.01505},{"month":5,"riseRate":0.555556,"avgChangeRate":0.018382},{"month":6,"riseRate":0.688889,"avgChangeRate":0.026171},{"month":7,"riseRate":0.488889,"avgChangeRate":-0.001692},{"month":8,"riseRate":0.533333,"avgChangeRate":0.006145},{"month":9,"riseRate":0.555556,"avgChangeRate":-0.002979},{"month":10,"riseRate":0.488889,"avgChangeRate":-0.004606},{"month":11,"riseRate":0.6,"avgChangeRate":0.026574},{"month":12,"riseRate":0.733333,"avgChangeRate":0.048757}],"exchange":"NYSE","name":"诺和诺德","nameEN":"Novo-Nordisk A/S"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺和诺德(NVO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺和诺德,NVO,诺和诺德股票,诺和诺德股票老虎,诺和诺德股票老虎国际,诺和诺德行情,诺和诺德股票行情,诺和诺德股价,诺和诺德股市,诺和诺德股票价格,诺和诺德股票交易,诺和诺德股票购买,诺和诺德股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺和诺德(NVO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}